Methylation markers for diagnosing hepatocellular carcinoma and lung cancer
AssigneesYouHealth Oncotech, Limited, The Regents of the University of California
InventorsKang ZHANG, Rui HOU, Lianghong ZHENG
Life of this patent
Estimating the term…
Abstract
Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are methods of determining the prognosis of the subject having HCC or lung cancer. In additional instances, described herein are methods of determining the specific staging of HCC or lung cancer in a subject.
Claims22
1-30. (canceled)
A method of determining a methylation profile of a subject, wherein the methylation profile comprises one or more markers, the method comprising:
- (a) contacting treated DNA from the subject with one or more probes to generate amplified products,
- wherein each probe hybridizes to the treated DNA to detect the methylation status of the one or more markers,
- wherein each of the one or more markers is selected from the group consisting of cg10673833, cg11225410, cg00338116, cg00552226, cg24496475, cg05414338, cg12041340, cg08343881, cg03431741, cg17126142, cg18004756, cg26205771, cg08436738, cg01604601, cg27252696, cg24917945, cg11252953, cg03550506, cg06903569, cg12865837, cg18440897, cg19255783, and cg20634573, and
- wherein the treated DNA is processed from a biological sample obtained from the subject to allow for determination of the methylation status of the one or more markers;
- and
- (b) analyzing the amplified products to generate the methylation status of the one or more markers,
- thereby determining the methylation profile of the one or more markers in the subject.
The method of any preceding claim, wherein the biological sample is a blood sample, tissue biopsy sample, or a circulating tumor cell sample.
Dependencies are inferred from the claim text.